Latest News

(UroToday.com) In this abstract, at the 2021 European Association of Urology (EAU) annual meeting, Dr. Cosimo De Nunzio et al. evaluate the safety of sequential Mitomycin-C (MMC) and Bacillus Calmette-Guérin (BCG) therapy compared to BCG monotherapy in patients with high risk non-muscle invasive bladder cancer (MIBC). The study is entitled MITOBCG and this abstract presentation highlights […]

(UroToday.com) At the non-muscle invasive bladder cancer (NMIBC) treatment and prognosis session at the European Association of Urology 2021 annual meeting Dr. Pietro Diana presented interim results of a single-center prospective randomized trial assessing en-bloc versus conventional transurethral resection of bladder tumors (TURBT). TURBT is considered the gold standard in the diagnosis and risk stratification of […]

(UroToday.com) Josias Grogg presented results of a study assessing the diagnostic accuracy of PSMA-PET-CT for pelvic lymph node staging in men with prostate cancer undergoing radical prostatectomy and pelvic lymph node dissection at the European Association of Urology 2021 annual meeting’s metastatic prostate cancer session. In men with newly diagnosed prostate cancer, only limited data describes […]

(UroToday.com) At the non-muscle invasive bladder cancer (NMIBC) treatment and prognosis session at the European Association of Urology (EUA) 2021 annual meeting, Dr. Diego M. Carrion Monsalve discussed preliminary results of the PRECAVE randomized controlled trial assessing the effect of a neoadjuvant instillation of chemotherapy in the prevention of recurrences of NMBIC. Approximately half of patients […]

(UroToday.com) Yasuyoshi Miyata from Japan presented results of a randomized clinical trial of intravesical mitomycin C plus cytarabine (Ara-C) versus mitomycin C for patients with non-muscle invasive bladder cancer (NMIBC) at the European Association of Urology 2021 annual meeting.

(UroToday.com) At the European Association of Urology 2021 annual meeting, Dr. Vikram M. Narayan, from Emory University presented results of several key subgroup analyses from the recently published trial assessing nadofaragene firadenovec in BCG-unresponsive NMIBC. The goals of treatment of NMIBC are to reduce recurrence and prevent progression, however, despite optimal treatment, ≥50% of patients who […]

(UroToday.com) At the 2021 European Association of Urology annual meeting, Vikram Narayan, discussed results of additional analysis assessing anti-adenovirus antibody response correlating with efficacy among patients in the phase III trial assessing nadofaragene firadenovec in patients with BCG unresponsive non-muscle invasive bladder cancer (NMIBC). This study was recently published in Lancet Oncology1. Nadofaragene firadenovec is a […]

San Francisco, CA (UroToday.com) — A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association […]

San Francisco, CA (UroToday.com) — Obese patients with a form of advanced prostate cancer survive longer than overweight and normal weight patients, new research has found.

Prof. Albersen (BE) hosts this edition of EAU TV, welcoming Profs. Mottrie (BE), Fizazi (FR) and Gillessen (CH) to discuss today’s plenary sessions. Topics include suitable applications for robotic surgery, the VISION study and treatment sequencing in metastatic prostate cancer. This article was first published here. The post EAU TV: Robotic surgery and advanced prostate […]